Test validation and availability

IndiTreat® is ready for your patients today

IndiTreat® Colorectal Cancer Sensitivity Test is a CE IVD validated test available throughout the EU and the UK.

IndiTreat® tests are performed at 2cureX laboratories in Europe. We can perform tests on your patients and can compare to results from reference patients.

Drug sensitivity testing on patient-derived 3D microtumors can provide vital information for every individual patient, and improve the likelihood of success of cancer treatment. IndiTreat® is a useful complement to the advances achieved in individual patient genomic characterization of tumors.

Improving the likelihood of success of cancer treatment

2cureX, pioneers in the use of 3D microtumors in cancer therapy, are empowering oncologists to select treatments more efficiently and thereby improve treatment outcomes.

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

June 2, 2021

Redeye Growth Day 2021, Stockholm

Read more

August 28, 2021

Interim Report Q2 2021

View previous reports

November 25, 2021

Interim Report Q3 2021

View previous reports

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs